[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07277413":3,"trial-entities:NCT07277413":414,"trial-summary:NCT07277413":437},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":32,"study_type":48,"primary_purpose":49,"phases":50,"enrollment_info":52,"interventions":55,"primary_outcomes":67,"secondary_outcomes":80,"sex":128,"minimum_age":129,"maximum_age":130,"healthy_volunteers":131,"eligibility_criteria":132,"std_ages":175,"locations":178,"central_contacts":403,"overall_officials":408,"references":412,"see_also_links":413},"NCT07277413","IDE892-001","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors","RECRUITING","2028-04-30","2026-08","2026-08-05","2026-03-04","IDEAYA Biosciences","INDUSTRY",true,"This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.","The purpose of this study is to evaluate safety, efficacy, and PK of IDE892 as monotherapy and combination therapy in adult participants with MTAP-deleted tumors who have progressed after standard therapy and represent a high unmet need. In the current stage, the combination will be focused on IDE892 with IDE397, an oral inhibitor of methionine adenosyltransferase 2A (MAT2A), to fully exploit the vulnerabilities associated with methylthioadenosine (MTA) accumulation in MTAP-deleted tumors while maintaining a substantial therapeutic index. The mechanistic rationale for this study is discussed in the following sections.",[19,20,21,22,23,24,25,26,27,28,29,30,31],"NSCLC Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastric Adenocarcinoma","Adenocarcinoma of Esophagus","Squamous Cell Car. - Esophagus","Urothelial Carcinoma (UC)","Bladder Cancer","Mesothelioma","Pleural Mesothelioma","Peritoneal Mesothelioma","Non-Small Cell Lung Cancer NSCLC","Pancreatic Cancer","Biliary Tract Carcinoma",[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"MTAP deletion","MTAP loss","MTAP-deficient tumors","homozygous MTAP loss","IDE892","IDE397","MAT2A inhibitor","PRMT5","advanced solid tumors","metastatic cancer","recurrent cancer","dose escalation","dose expansion","phase 1 clinical trial","ctDNA","INTERVENTIONAL","TREATMENT",[51],"PHASE1",{"count":53,"type":54},260,"ESTIMATED",[56,64],{"type":57,"name":37,"description":58,"armGroupLabels":59},"DRUG","IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions.",[60,61,62,63],"Part 1: IDE892 Monotherapy Dose Escalation (MTAP-deleted advanced solid tumors)","Part 2: IDE892 Monotherapy Dose Expansion (MTAP-Deleted NSCLC)","Part 3: IDE892 + IDE397 Combination Dose Escalation (MTAP-Deleted Solid Tumors)","Part 4: IDE892 + IDE397 Combination Dose Expansion (MTAP-Deleted NSCLC)",{"type":57,"name":38,"description":65,"armGroupLabels":66},"IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors.",[62,63],[68,72,76],{"measure":69,"description":70,"timeFrame":71},"Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)","Incidence of DLTs of IDE892 will be determined in Parts 1 and 3","21 days following the first dose of IDE892 (each cycle is 21 days)",{"measure":73,"description":74,"timeFrame":75},"Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)","Incidence and severity of adverse events (AEs)\u002Fserious adverse events (SAEs) (graded based on Common Terminology Criteria for Adverse Events \\[CTCAE\\] version 5.0) will be determined in Parts 1, 2, 3, and 4.","From first dose until 28 days after last dose (each cycle is 21 days)",{"measure":77,"description":78,"timeFrame":79},"Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)","Objective response rate (ORR: best objective response of complete response \\[CR\\] + partial response \\[PR\\]) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the Investigator","Approximately 2 years",[81,84,87,91,94,97,100,103,106,110,113,116,119,122,125],{"measure":82,"description":83,"timeFrame":79},"Overall response rate (ORR) and duration of response (DOR) per RECIST version 1.1 (Parts 1 and 3)","ORR and DOR per RECIST version 1.1 as assessed by the Investigator",{"measure":85,"description":86,"timeFrame":79},"Disease control rate (DCR) and duration of stable disease per RECIST version 1.1 (Parts 1, 2, 3, and 4)","Disease control rate (disease control rate \\[DCR\\]: CR + PR + stable disease \\[SD\\]) and duration of SD per RECIST version 1.1 as assessed by the Investigator",{"measure":88,"description":89,"timeFrame":90},"Maximum Observed Plasma Concentration (Cmax) (Parts 1, 2, 3, and 4)","Cmax is the highest observed plasma concentration of the study drug following administration of IDE892 as a single agent or in combination with IDE397","Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)",{"measure":92,"description":93,"timeFrame":90},"Time to Maximum Observed Concentration (Tmax)","Time to Maximum Observed Concentration (Tmax) after administration of IDE892 as a single agent or in combination with IDE397",{"measure":95,"description":96,"timeFrame":90},"Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)","AUClast reflects total drug exposure from dosing until the last measurable concentration after administration of IDE892 as a single agent or in combination with IDE397",{"measure":98,"description":99,"timeFrame":90},"Time of Last Quantifiable Concentration (Tlast)","Tlast is the time at which the final measurable drug concentration is observed after administration of IDE892 as a single agent or in combination with IDE397",{"measure":101,"description":102,"timeFrame":90},"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf)","AUCinf represents total drug exposure extrapolated to infinite time after administration of IDE892 as a single agent or in combination with IDE397",{"measure":104,"description":105,"timeFrame":90},"Terminal Elimination Half-Life (t½)","t½ is the time required for the plasma concentration of the drug to decrease by half during the terminal elimination phase after administration of IDE892 as a single agent or in combination with IDE397",{"measure":107,"description":108,"timeFrame":109},"Maximum Observed Plasma Concentration at Steady State (Cmax,ss)","Cmax,ss is the maximum observed plasma concentration after achieving steady state after administration of IDE892 as a single agent or in combination with IDE397","Cycle 1 Day 15 (each cycle is 21 days)",{"measure":111,"description":112,"timeFrame":109},"Time to Maximum Concentration at Steady State (Tmax,ss)","Tmax,ss is the time from dosing to Cmax at steady state after administration of IDE892 as a single agent or in combination with IDE397",{"measure":114,"description":115,"timeFrame":109},"Trough Plasma Concentration at Steady State (Ctrough)","Ctrough is the concentration obtained immediately prior to the next scheduled dose at steady state after administration of IDE892 as a single agent or in combination with IDE397",{"measure":117,"description":118,"timeFrame":109},"Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau)","AUCtau represents drug exposure over one full dosing interval at steady state after administration of IDE892 as a single agent or in combination with IDE397",{"measure":120,"description":121,"timeFrame":90},"Apparent Clearance (CL\u002FF)","CL\u002FF is the apparent clearance of the drug after extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397",{"measure":123,"description":124,"timeFrame":90},"Apparent Volume of Distribution (Vz\u002FF)","Vz\u002FF is the apparent volume of distribution following extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397",{"measure":126,"description":127,"timeFrame":90},"Accumulation Ratio (Rac)","Rac is calculated as the ratio of AUC or Cmax at steady state compared with first dose, reflecting drug accumulation after administration of IDE892 as a single agent or in combination with IDE397","ALL","18 Years",null,false,{"inclusion":133,"exclusion":146,"raw_text":174},[134,135,136,137,138,139,140,141,142,143,144,145],"Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.","Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma \\[pleural or peritoneal\\], gastroesophageal cancers \\[squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers\\], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC \\[adenocarcinoma, squamous cell carcinoma, and adeno-squamous\\] or UC \\[including mixed urothelial-squamous histology\\]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).","Are willing and able to provide blood\u002Ftumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.","Must be willing and able to provide the blood\u002Fserum\u002Fplasma samples","Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)","Have at least 1 measurable lesion according to RECIST version 1.1","Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1","Have life expectancy \\> 3 months","Have adequate bone marrow and organ function","Able to swallow and retain orally administered study drug\u002FIMP.","Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures","Male and female: willing to use contraception",[147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173],"Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids","Have a known primary central nervous system (CNS) malignancy","Have had other malignancies within 2 years prior to the first dose, with some exceptions","Impaired cardiac function or clinically significant cardiac diseases","Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter","Have a history of severe infections within 4 weeks prior to the start of study treatment","Hypertension (e.g., \\> 150\u002F100 mmHg) that cannot be controlled by medications despite optimal medical therapy","Other acute or chronic medical or psychiatric condition","Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening","Known or suspected viral hepatitis with a positive test at screening","Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1","Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks","Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP","Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein","Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4\u002F5, Strong inhibitors of P-gp and\u002For BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP","Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study","Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892","Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and\u002For Protein arginine N-methyltransferase (PRMT) inhibitor","Major surgery within 4 weeks before study entry","Prior irradiation to \\> 25% of the bone marrow","Known or suspected hypersensitivity to IDE892","Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1\u002FPD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting","Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.","If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.","Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors","Must have progressed following at least 1 prior line of therapy","Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease","Inclusion Criteria:\n\n* Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.\n* Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma \\[pleural or peritoneal\\], gastroesophageal cancers \\[squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers\\], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC \\[adenocarcinoma, squamous cell carcinoma, and adeno-squamous\\] or UC \\[including mixed urothelial-squamous histology\\]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).\n* Are willing and able to provide blood\u002Ftumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.\n* Must be willing and able to provide the blood\u002Fserum\u002Fplasma samples\n* Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)\n* Have at least 1 measurable lesion according to RECIST version 1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1\n* Have life expectancy \\> 3 months\n* Have adequate bone marrow and organ function\n* Able to swallow and retain orally administered study drug\u002FIMP.\n* Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures\n* Male and female: willing to use contraception\n\nExclusion Criteria:\n\n* Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids\n* Have a known primary central nervous system (CNS) malignancy\n* Have had other malignancies within 2 years prior to the first dose, with some exceptions\n* Impaired cardiac function or clinically significant cardiac diseases\n* Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter\n* Have a history of severe infections within 4 weeks prior to the start of study treatment\n* Hypertension (e.g., \\> 150\u002F100 mmHg) that cannot be controlled by medications despite optimal medical therapy\n* Other acute or chronic medical or psychiatric condition\n* Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening\n* Known or suspected viral hepatitis with a positive test at screening\n* Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1\n* Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks\n* Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP\n* Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein\n* Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4\u002F5, Strong inhibitors of P-gp and\u002For BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP\n* Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study\n* Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892\n* Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and\u002For Protein arginine N-methyltransferase (PRMT) inhibitor\n* Major surgery within 4 weeks before study entry\n* Prior irradiation to \\> 25% of the bone marrow\n* Known or suspected hypersensitivity to IDE892\n\nDisease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)\n\n* Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1\u002FPD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting\n* Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.\n* If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.\n\nEligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)\n\n* Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors\n* Must have progressed following at least 1 prior line of therapy\n* Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease",[176,177],"ADULT","OLDER_ADULT",[179,194,210,223,235,251,264,276,288,301,318,331,343,352,364,377,390],{"facility":180,"status":8,"city":181,"state":182,"zip":183,"country":184,"contacts":185,"geoPoint":191},"Providence Medical Foundation","Santa Rosa","California","95403","United States",[186],{"name":187,"role":188,"phone":189,"email":190},"Ian Anderson, MD","CONTACT","707-521-3830","ian.anderson@providence.org",{"lat":192,"lon":193},38.44047,-122.71443,{"facility":195,"status":8,"city":196,"state":197,"zip":198,"country":184,"contacts":199,"geoPoint":207},"Johns Hopkins Sibley Memorial Hospital","Washington D.C.","District of Columbia","20016",[200,204],{"name":201,"role":188,"phone":202,"email":203},"Solmaz Sahebjam, MD","202-669-6500","ssahebj1@jh.edu",{"name":205,"role":188,"phone":202,"email":206},"Mahlet Atnafu","SibleyOncResReferral@live.johnshopkins.edu",{"lat":208,"lon":209},38.89511,-77.03637,{"facility":211,"status":8,"city":212,"state":213,"zip":214,"country":184,"contacts":215,"geoPoint":220},"BRCR Global-Coral Springs","Coral Springs","Florida","33065",[216],{"name":217,"role":188,"phone":218,"email":219},"Alina Quintana","561-447-0614","alinaq@brcrglobal.com",{"lat":221,"lon":222},26.27119,-80.2706,{"facility":224,"status":8,"city":225,"state":213,"zip":226,"country":184,"contacts":227,"geoPoint":232},"Sarah Cannon Research Institute at Florida Cancer Specialists","Orlando","32827",[228],{"name":229,"role":188,"phone":230,"email":231},"Elizabeth Gilmore","904-380-2410","Elizabeth.Griffith@Scri.com",{"lat":233,"lon":234},28.53834,-81.37924,{"facility":236,"status":8,"city":237,"state":213,"zip":238,"country":184,"contacts":239,"geoPoint":248},"Moffitt Cancer Center","Tampa","33612",[240,244],{"name":241,"role":188,"phone":242,"email":243},"Mauricio Ribeiro, MD","813-745-3242","mauricio.ribeiro@moffitt.org",{"name":245,"role":188,"phone":246,"email":247},"Anisa Gonzalez","813-745-3874","anisa.gonzalez@moffitt.org",{"lat":249,"lon":250},27.94752,-82.45843,{"facility":252,"status":8,"city":253,"state":254,"zip":255,"country":184,"contacts":256,"geoPoint":261},"Nebraska Cancer Specialists","Omaha","Nebraska","68130",[257],{"name":258,"role":188,"phone":259,"email":260},"Lindsey Becker, Primary Study Coordinator","402-691-5255","lbecker@nebraskacancer.com",{"lat":262,"lon":263},41.25626,-95.94043,{"facility":265,"status":8,"city":266,"state":267,"zip":268,"country":184,"contacts":269,"geoPoint":273},"START Astera, LLC","East Brunswick","New Jersey","08816",[270],{"name":271,"role":188,"email":272},"Hope Team Distribution List","hopeteam@startresearch.com",{"lat":274,"lon":275},40.42788,-74.41598,{"facility":277,"status":8,"city":278,"state":278,"zip":279,"country":184,"contacts":280,"geoPoint":285},"Columbia University Irving Medical Center","New York","10032",[281],{"name":282,"role":188,"phone":283,"email":284},"Nurse Navigation Team: Contact for All Patient Referrals","212-342-5162","cancerclinicaltrials@cumc.columbia.edu",{"lat":286,"lon":287},40.71427,-74.00597,{"facility":289,"status":8,"city":290,"state":291,"zip":292,"country":184,"contacts":293,"geoPoint":298},"Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University","Philadelphia","Pennsylvania","19107",[294,297],{"name":295,"role":188,"phone":296},"askphase1@jefferson.edu","215-586-0199",{"role":188,"email":295},{"lat":299,"lon":300},39.95238,-75.16362,{"facility":302,"status":8,"city":303,"state":304,"zip":305,"country":184,"contacts":306,"geoPoint":315},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",[307,311],{"name":308,"role":188,"phone":309,"email":310},"Alydia Miller","615-927-2212","alydia.miller@scri.com",{"name":312,"role":188,"phone":313,"email":314},"Sarah Cannon Institute","844-482-4812","asksarah@sarahcannon.com",{"lat":316,"lon":317},36.16589,-86.78444,{"facility":319,"status":8,"city":320,"state":321,"zip":322,"country":184,"contacts":323,"geoPoint":328},"START Dallas Fort Worth","Fort Worth","Texas","76104",[324],{"name":325,"role":188,"phone":326,"email":327},"Kasie Newton","682-350-3010","kasie.newton@startresearch.com",{"lat":329,"lon":330},32.72541,-97.32085,{"facility":332,"status":8,"city":333,"state":321,"zip":334,"country":184,"contacts":335,"geoPoint":340},"MD Anderson","Houston","77030",[336],{"name":337,"role":188,"phone":338,"email":339},"Jordi Rodon Ahnert, MD, PhD","713-563-1930","JRodon@mdanderson.org",{"lat":341,"lon":342},29.76328,-95.36327,{"facility":344,"status":8,"city":333,"state":321,"zip":345,"country":184,"contacts":346,"geoPoint":351},"NEXT Oncology Houston","77054",[347],{"name":348,"role":188,"phone":349,"email":350},"Emma Morales","832-384-7912","emorales@nextoncology.com",{"lat":341,"lon":342},{"facility":353,"status":8,"city":354,"state":321,"zip":355,"country":184,"contacts":356,"geoPoint":361},"NEXT Oncology Dallas","Irving","75039",[357],{"name":358,"role":188,"phone":359,"email":360},"Mofopefoluwa Akinwale","972-893-8800","fakinwale@nextoncology.com",{"lat":362,"lon":363},32.81402,-96.94889,{"facility":365,"status":8,"city":366,"state":367,"zip":368,"country":184,"contacts":369,"geoPoint":374},"START Mountain Region, LLC","West Valley City","Utah","84119",[370],{"name":371,"role":188,"phone":372,"email":373},"Marie Asay, Director, Nursing","801-907-4770","marie.asay@startresearch.com",{"lat":375,"lon":376},40.69161,-112.00105,{"facility":378,"status":8,"city":379,"state":380,"zip":381,"country":184,"contacts":382,"geoPoint":387},"NEXT Oncology Virginia","Fairfax","Virginia","22031",[383],{"name":384,"role":188,"phone":385,"email":386},"Maybelle De La Rosa","703-783-4518","mdelarosa@nextoncology.com",{"lat":388,"lon":389},38.84622,-77.30637,{"facility":391,"status":8,"city":392,"state":393,"zip":394,"country":184,"contacts":395,"geoPoint":400},"Swedish Cancer Institute","Seattle","Washington","98104",[396],{"name":397,"role":188,"phone":398,"email":399},"Siddhartha Devarakonda, MD","206-386-2424","siddhartha.devarakonda@swedish.org",{"lat":401,"lon":402},47.60621,-122.33207,[404],{"name":405,"role":188,"phone":406,"email":407},"IDEAYA Clinical Trials","+1 855 433 2246","IDEAYAClinicalTrials@ideayabio.com",[409],{"name":410,"affiliation":13,"role":411},"Edward Chan, MD","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":415,"biomarkers":434},[416,417,31,418,419,420,421,21,422,423,424,425,426,427,428,429,430,431,432,433],"Adenosquamous Carcinoma","Anal Adenocarcinoma","Esophageal Adenocarcinoma","Esophageal Squamous Cell Carcinoma","Extrahepatic Cholangiocarcinoma","Gallbladder Carcinoma","Gastroesophageal Junction Adenocarcinoma","Intrahepatic Cholangiocarcinoma","Lung Non-Small Cell Carcinoma","Malignant neoplasm of cardio-esophageal junction of stomach","Mesothelial Neoplasm","Mixed Urothelial-Squamous Carcinoma","Pancreatic Adenocarcinoma","Peritoneal Malignant Mesothelioma","Pleural Malignant Mesothelioma","Solid Neoplasm","Squamous Cell Carcinoma","Urothelial Carcinoma",[435,436],"MTAP Gene","PRMT5 Gene",{"nct_id":4,"found":15,"summary":438,"prompt_version":448},{"design":439,"status":440,"heading":441,"summary":442,"follow_up":443,"word_count":444,"commitments":445,"compensation":446,"drugs_mentioned":447},"This is a multi-center interventional study, meaning participants will receive a specific treatment. The study plans to enroll 260 participants.","completed","A Study of IDE892 for MTAP-deleted Advanced Solid Tumors","This study is testing a new drug called IDE892, by itself and in combination with another drug called IDE397, for people with advanced solid tumors that have a specific genetic change called an MTAP deletion. The study is looking at how safe these drugs are and how well they work. You might be able to join if you are 18 or older and have certain types of advanced solid tumors with an MTAP deletion, such as lung, gastroesophageal, or gastric cancers, that have continued to grow after standard treatments. The researchers will measure side effects (adverse events) and how many people respond to the treatment and for how long. The study aims to enroll about 260 participants.","Participants will be followed for side effects from the first dose until 28 days after the last dose. The response to treatment will be measured for approximately 2 years.",117,"Not specified in the trial record.","Not stated in the trial record.",[37,38],"v2"]